Merck to Divide Pharmaceutical Unit Ahead of Patent Expiry

Merck is set to divide its primary pharmaceutical division into two separate entities in anticipation of the patent expiration of its top-selling medication. Bloomberg posted on X, highlighting the company's strategic move to address the challenges posed by the impending loss of exclusivity. This decision reflects Merck's efforts to adapt to the evolving pharmaceutical landscape and maintain its competitive edge in the market. The split aims to streamline operations and focus on innovation, ensuring sustained growth and development in the face of patent challenges.